Pathophysiology of the pain of fibromyalgia;Physiopathologie de la douleur de la fibromyalgie

Revue du Rhumatisme (Edition Francaise)

Volumn 70, Issue 4, 2003, Pages 314-320

  Houvenagel, Éric ^a  

^a Centre Hospitalier Saint Philibert GHICL   (France)

Author keywords

Allodynia; Fibromyalgia; Growth hormone; Muscle; Neuromediator; Serotonin

Indexed keywords

ACETIC ACID DERIVATIVE; ADENOSINE TRIPHOSPHATE; CARBON DIOXIDE; N METHYL DEXTRO ASPARTIC ACID; NERVE GROWTH FACTOR; SEROTONIN; SUBSTANCE P;

DEPRESSION; DISEASE PREDISPOSITION; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC SUSCEPTIBILITY; HUMAN; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INCIDENCE; MUSCLE FATIGUE; NEUROENDOCRINOLOGY; NEUROMODULATION; NOCICEPTION; PAIN; PATHOPHYSIOLOGY; PSYCHOBIOLOGY; PSYCHOGENIC PAIN; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECTROSCOPY; SYMPTOMATOLOGY;

EID: 0347288223     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(03)00101-7     Document Type: Article

References (49)

1. Bengtsson A, Henriksson KG. The muscle biopsy in fibromyalgia - A review of Swedish studies. J Rheumatol 1989;16:144-9.
2. Yunus MB, Kalyan-Raman UP, Masi AT. Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol 1992;16:97-101.
3. Sprott H, Rzanny R, Reichenbach JR, Kaiser WA, Hein G, Stein G. 31p magnetic resonance spectroscopy in fibromyalgic muscle. Rheumatology 2000;39:1121-5.
4. Simms RW. Fibromyalgia is not a muscle disorder. Am J Med Sci 1998;315:346-50.
5. Hudson JI, Hudson MS, Pliner LF, Goldenberg DL, Pope HG. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985;142:441-6.
6. Hudson JI, Goldenberg DL, Pope HG, Keck PE, Schlessinger L. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992;92:363-7.
7. Wolfe F, Cathey MA, Kleinheksel SM, Amos SP, Hoffman RG, Young DY, et al. Psychological status in primary fibrositis and fibrositis associated with rheumatoid arthritis. J Rheumatol 1984;11:500-6.
8. Ahles TA, Kahn SA, Yunus MB, Spiegel DA, Masi AT. Psychiatric status of patients with primary fibromyalgia, patients with rheumatoid arthritis, and subjects without pain: a blind comparison of DSM-III diagnoses. Am J Psychiatry 1991;148:1721-6.
9. Clark S, Campbell SM, Forehand ME, Tindall EA, Bennet RM. Clinical characteristics of fibrositis. II. A "blinded" controlled study using standard psychological tests. Arthritis Rheum 1985;28:132-7.
10. Fasbender K, Samborsky W, Kellner M, Muller W, Lautenbacher S. Tender points, depressive and functionnal symptoms: comparison between fibromyalgia and major depression. Clin Rheumatol 1997; 16:76-9.
11. Okifuji A, Turk DC, Sherman JJ. Evaluation of the relationship between depression and fibromyalgia syndrome: Why aren't all patients depressed? J Rheumatol 2000;27:212-9.
12. Cianfrini LR, McKebdree Smith NL, Bradley LA, Alarcon GS, Deutsch G, Sodolongo A, et al. Pain sensitivity and bilateral activation of brain structures during pressure stimulation of patients with fibromyalgia is not mediated by major depression [résumé]. Arthritis Rheum 2001;44(suppl):S395.
13. Hudson JI, Pope HG. Fibromyalgia and psychopathology: is fibromyalgia a form of "affective spectrum disorder?". J Rheumatol 1989;16: 15-22.
14. Weigent DA, Bradley LA, Blalock JE, Alarcon S. Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998;315:405-12.
15. Bradley LA, Alarcon GS, Triana M. Health care seeking behavior in fibromyalgia: associations with pain thresholds, symptom severity, and psychiatric morbidity. J Musculoskel Pain 1994;2:79-87.
16. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997;40:1928-39.
17. Kosek E, Elkolm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996;68: 375-83.
18. 2 laser stimulation in subjects with fibromyalgia syndrome. Pain 1994;58:185-93.
19. Lautenbacher S, Rollman GB. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997;13:189-96.
20. Staud R, Robinson ME, Vierck CJ, Price DD. Diffuse noxious inhibitory controls (DNIC) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 2003;101:167-74.
21. Sorensen J, Graven-Nielsen T, Henriksson KG, Bengtsson M, Arendt-Nielsen L. Hyperexitability in fibromyalgia. J Rheumatol 1998;25: 152-5.
22. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sorensen J, Johnson A, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000;85:483-91.
23. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients with healthy subjects. Pain 1997;70: 41-51.
24. Coderre TJ, Katz J, Vaccarino AL, Melszack R. Contribution of central neuroplasticity to pathological pain: review of clinical experimental evidence. Pain 1993;52:259-85.
25. Hogeweg JA, Kuis W, Oosten Durp RAB, Helders PJM. General and segmental reduced pain in juvenile chronic arthritis. Pain 1995;62: 11-7.
26. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F. Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997;40: 446-52.
27. Mountz JM, Bradley LA, Modell JG, Alexander RW, Aaron LA, Triana M, et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38: 926-38.
28. Gracely R, Petzke F, Wolf JM, Clauw D. Functionnal magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002;46:1333-43.
29. Goldstein JA. Fibromyalgia syndrome: a pain modulation disorder related to altered limbic function? Ballière's Clin Rheumatol 1994;8: 777-800.
30. Houvenagel E, Forzy G, Leloire O, Gallois P, Hary S, Hautecoeur P, et al. Mono-amines du liquide céphalo-rachidien dans la fibromyalgie primitive. Rev Rhum Mal Ostéoartic 1990;57:21-3.
31. Russel IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia / fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6.
32. Thomas E, Blotman F. Les traitements antidépresseurs améliorent-ils vraiment la fibromyalgie ? Rev Rhum 2002;69:1165-7.
33. Farber L, Stratz T, Brukle W, Spath M, Pongratz D, Lautenschlager J, et al. Efficacity and tolerability of tropisetron in primary fibromyalgia - a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol Suppl 2000;113:49-54.
34. Offenbaecher M, Bondy B, De Jonge S, Glatzeder K, Kruger M, Schoeps P, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42:2482-8.
35. Houvenagel E. Les mécanismes de la douleur de la fibromyalgie. Rev Rhum 1999;66:105-10 [Ed Fr].
36. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, 2 faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol 1996;398:373-9.
37. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 1994;40: 288-95.
38. Goldberg PA, Kamm MA, Setti-Carraro P, van der Slijp JR, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (odonsedron). Digestion 1996;57: 478-83.
39. Vareroy H, Helle R, Forre O, Kass E, Terenius L. Crebrospinal fluid levels of beta-endorphin in patients with fibromyalgia (fibrositis syndrome). J Rheumatol 1988;15:1804-6.
40. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalej JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37: 1593-601.
41. Giovengo SL, Russel IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999;26:1564-9.
42. Fasi TM, Russel IJ, Xiao YM, Lambert PJ. Nocistatin-binding and nociceptin-binding autoantibodies in a subset of fibromyalgia patients. Arthritis Rheum 2001;44(suppl):S69.
43. Russel IJ. Advances in fibromyalgia: possible role for central neurochemicals. Am J Med Sci 1998;315:377-84.
44. Schlinger JL, Perrin AE, Grunenberg F, Goichot B. Hormonal perturbations in fibromyalgia. Ann Endocrinol 2001;62:542-8.
45. Parker AJ, Wessely S, Cleare AJ. The neuro-endocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med 2001;31:1331-45.
46. Amir M, Kaplan Z, Neuman L, Sharabini R, Shani N, Buskila D. Post-traumatic disorder, tenderness and fibromyalgia. J Psychom Res 1997;42:607-13.
47. Bennet RM, Cook DM, Clarck SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997;24:1384-9.
48. Older SA, Battafarano DF, Danning CL, Ward JA, Grady AP, Derman S, et al. The effects of delta sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects; correlations with insulin -like growth factor1. J Rheumatol 1998;25:1180-6.
49. Bennett RM, Clark SC, Walczyk JA. A randomised, double blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31.